DrugPatentWatch Database Preview
Teva Branded Pharm Company Profile
What is the competitive landscape for TEVA BRANDED PHARM, and what generic alternatives to TEVA BRANDED PHARM drugs are available?
There are forty-three US patents protecting TEVA BRANDED PHARM drugs.
There are five hundred and fifty-seven patent family members on TEVA BRANDED PHARM drugs in thirty-six countries and thirteen supplementary protection certificates in nine countries.
Summary for Teva Branded Pharm
| International Patents: | 557 |
| US Patents: | 43 |
| Tradenames: | 22 |
| Ingredients: | 13 |
| NDAs: | 23 |
| Patent Litigation for Teva Branded Pharm: | See patent lawsuits for Teva Branded Pharm |
Drugs and US Patents for Teva Branded Pharm
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva Branded Pharm | NASAREL | flunisolide | SPRAY, METERED;NASAL | 020409-001 | Mar 8, 1995 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | |||||
| Teva Branded Pharm | PROAIR RESPICLICK | albuterol sulfate | POWDER, METERED;INHALATION | 205636-001 | Mar 31, 2015 | RX | Yes | Yes | 7,540,282 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Teva Branded Pharm | PROAIR RESPICLICK | albuterol sulfate | POWDER, METERED;INHALATION | 205636-001 | Mar 31, 2015 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | |||||
| Teva Branded Pharm | PROAIR HFA | albuterol sulfate | AEROSOL, METERED;INHALATION | 021457-001 | Oct 29, 2004 | BX | RX | Yes | Yes | 9,463,289 | ➤ Sign Up | Y | ➤ Sign Up | ||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for Teva Branded Pharm
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Teva Branded Pharm | QVAR 40 | beclomethasone dipropionate | AEROSOL, METERED;INHALATION | 020911-002 | Sep 15, 2000 | 5,776,432 | ➤ Sign Up |
| Teva Branded Pharm | QNASL | beclomethasone dipropionate | AEROSOL, METERED;NASAL | 202813-002 | Dec 17, 2014 | 5,776,432 | ➤ Sign Up |
| Teva Branded Pharm | QVAR 80 | beclomethasone dipropionate | AEROSOL, METERED;INHALATION | 020911-001 | Sep 15, 2000 | 5,766,573 | ➤ Sign Up |
| Teva Branded Pharm | CENESTIN | estrogens, conjugated synthetic a | TABLET;ORAL | 020992-002 | Mar 24, 1999 | 5,908,638 | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for TEVA BRANDED PHARM drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 1.25 mg | ➤ Subscribe | 2008-11-03 |
| ➤ Subscribe | Tablets | 0.15 mg/0.03 mg | ➤ Subscribe | 2004-03-29 |
| ➤ Subscribe | Tablets | 0.3 mg, 0.45 mg and 0.9 mg | ➤ Subscribe | 2009-03-19 |
| ➤ Subscribe | Tablets | 0.15 mg/0.02 mg, 0.15 mg/0.025 mg, 0.15 mg/0.03 mg and 0.01 mg | ➤ Subscribe | 2013-07-10 |
| ➤ Subscribe | Tablets | 0.625 mg | ➤ Subscribe | 2009-03-02 |
| ➤ Subscribe | Tablets | 0.15 mg/0.03 mg/0.01 mg | ➤ Subscribe | 2008-01-22 |
| ➤ Subscribe | Tablets | 0.1 mg/0.02 mg and 0.01 mg | ➤ Subscribe | 2009-11-16 |
Premature patent expirations for TEVA BRANDED PHARM
Non-Orange Book US Patents for Teva Branded Pharm
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 9,108,010 | Dose counters for inhalers, inhalers and methods of assembly thereof | ➤ Sign Up |
| 8,227,454 | Estrogenic compounds, pharmaceutical compositions and formulations comprising the same | ➤ Sign Up |
| 7,179,799 | (3) and (6) substituted estrogenic compounds | ➤ Sign Up |
| 6,250,127 | Heat-dissipating aluminum silicon carbide composite manufacturing method | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
International Patents for Teva Branded Pharm Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Japan | 2004500396 | ➤ Sign Up |
| South Korea | 101718674 | ➤ Sign Up |
| China | 101472644 | ➤ Sign Up |
| Australia | 7011301 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for Teva Branded Pharm Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 2009 00017 | Denmark | ➤ Sign Up | PRODUCT NAME: ETHINYLESTRADIOL (SOM BETADEXCLATHRAT) OG DROSPIRENON; NAT. REG. NO/DATE: 42417 (DK) 20080619; FIRST REG. NO/DATE: NL 33842 20070629 |
| 0160011 00192 | Estonia | ➤ Sign Up | PRODUCT NAME: LEVONORGESTREEL JA ETUENUEUELOESTRADIOOL;REG NO/DATE: EE 894715 11.11.2015 |
| 2015000093 | Germany | ➤ Sign Up | PRODUCT NAME: LEVONORGESTREL UND ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: 87675.00.00 20150720; FIRST REGISTRATION: SLOWAKEI 17/0017/15-S 20150129 |
| /2015 | Austria | ➤ Sign Up | PRODUCT NAME: ETHINYLESTRADIOL UND EINE KOMBINATION VON LEVONORGESTREL UND ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: 136021 20150224; FIRST REGISTRATION: SK 17/0017/15-S 20150211 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
